Japan's Mitsubishi Tanabe Pharma Corporation announced the purchase of the Israeli company Neuroderm, which is developing new methods of treating central nervous system diseases.
The transaction value should be 1.1 billion dollars, which is 15% higher than the cost of shares of the Israeli company on Wall Street.
The company's leading product is Levodopa Carbidopa, a device for the administration of medications intended for the treatment of symptoms in the advanced stage of Parkinson's disease.
The company issued its shares on the NASDAQ high-tech exchange in 2014, and was valued by investors at $ 164 million